

FOR RELEASE JANUARY 17, 2012



Contact:

Tom Johnson

Tom.Johnson@pgxlab.com

502-569-0334

**JOINT VENTURE FORMED TO COMMERCIALIZE
RAPID DAYTIME TEST FOR SLEEP APNEA IN CHILDREN
Global Opportunity Emerges for Paradigm-Shifting Technology**

Louisville KY – PGXL/Laboratories and its sister company, PGXL/Technologies, have entered into a joint venture with Appian Partners LLC of Severna Park, Maryland, and Vanguard Technologies LLC, of Boston, Massachusetts, to develop and commercialize an innovative diagnostic test comprising a set of diagnostic biomarkers for Obstructive Sleep Apnea (OSA). The joint venture company, NuSomnea LLC, will locate corporate offices in Maryland and conduct research and development in Kentucky.

Early research conducted at the University of Louisville indicates a very high degree of accuracy in diagnosing sleep apnea without subjecting pediatric patients to polysomnography, an expensive and grueling overnight exam, or sleep diagnostic study that is particularly traumatic for children. NuSomnea will be seeking funding in 2012 to further develop and commercialize the biomarkers for pediatric OSA diagnosis.

“The successful development and commercialization of this diagnostic test has the possibility to change the way pediatric sleep medicine is practiced globally,” says Dr. Roland Valdes, Jr., chairman of PGXL. “It will make life easier for parents who have children suspected of having sleep apnea. Our goal is to demonstrate how our innovative technology can deliver superior clinical and financial outcomes to payors, parents, physicians, and hospitals.”

The biomarker set was identified by Dr. Valdes, Dr. Saed Jortani, Dr. David Ghozal and Dr. Leila Kheirandish-Gozal while working together in the University of Louisville Departments of Pathology and Laboratory Medicine, and Pediatrics.

Scientists estimate that between 12 million and 20 million people in the U.S. have sleep apnea. 2-3% of all children are suspected to have OSA. Approximately 6 million suffer moderate to severe sleep apnea – that is, sleep apnea pronounced enough to cause more serious health and behavioral issues. People with sleep apnea face significantly higher risk of hypertension, Type 2 diabetes, obesity and depression. According to the National Commission on Sleep Disorders Research, sleep apnea contributes significantly to 38,000 cardiovascular deaths annually. A University of Washington study estimated that undiagnosed sleep apnea costs the American healthcare system \$3.4 billion a year, or nearly \$2,000 per case.

NuSomnea intends to develop a diagnostic assay based on the biomarkers. That development will be done with PGXL/Technologies and its sister company, PGXL/Laboratories. The development will be conducted in the Nucleus Innovation Park in downtown Louisville. Developing the assay and conducting clinical trials will take from two to three years.

PGXL/Technologies develops intellectual property into clinical laboratory applications. It is a privately-held business located in Louisville, Kentucky. Its sister company, PGXL/Laboratories, was the first lab in the country CLIA-certified specifically to conduct pharmacogenetic tests.

PGXL performs clinical laboratory tests, contract research for manufacturers of pharmaceuticals and medical equipment, and has developed PerMIT, a software platform currently in clinical trials that helps physicians apply genetic information to the treatment of individual patients.

NuSomnea LLC is a Maryland-based company formed to bring to market technologies to diagnose and treat sleep apnea.